News

For drug developers, oncology therapeutics arguably represent both the greatest opportunity and challenge for putting patients at the center. This ebook covers series strategies for Advancing Oncology Drug Development with ePRO Solutions.

Given the wide use of digital technologies in society today, apprehension about implementing eCOA and creating an eCOA back-up plan is unwarranted.

After a court case rehashes the issue of excessive secrecy in trial data, drug firms maintain their objections over releasing data on their products.

The time to stop hammering square pegs into round holes in terms of design strategy has come, as sponsors embrace an adaptive supply chain approach.

With a month left to join one of the 24 ERNs, Peter O'Donnell writes that this initiative is a welcomed demonstration of how cooperation can function in the common interest.

Darren Davis, Senior Vice President at Precision for Medicine, explores the need for specialty labs in cancer treatment plans.

As a new industry survey shows, factoring in a generational cohort surfaces some provocative results related to key health indicators in clinical outsourcing relationships.

The latest happenings in the clinical trials industry, all in one place.